Latest Product Development News

Firebrick Pharma reports a $1.94 million cash reserve after a $1.4 million placement, supporting expanded Nasodine sales across Southeast Asia and the US. Board changes and increased operational costs mark a pivotal quarter for the pharmaceutical innovator.

Nordic Resources has raised A$8.5 million in a strongly supported institutional placement to fund expanded exploration and development of its Finnish gold projects, with key assay results imminent.

Codan Limited reported a strong FY25 with significant revenue and profit growth, bolstered by a key U.S. acquisition and a robust outlook for FY26 driven by defense spending and gold market strength.

Vitrafy Life Sciences has delivered its first production unit of the next-generation cryopreservation device, advanced its US commercial footprint, and maintained a strong financial position heading into FY2026.

Miramar Resources has granted Future Battery Minerals an exclusive option to acquire its Randalls Project for up to A$800,000, enabling a strategic refocus on its core gold and critical minerals assets.

Mayne Pharma has announced the rescheduling of its Supreme Court hearing to November 3, 2025, to approve the acquisition scheme by Cosette Australia BidCo, pending Foreign Investment Review Board approval.

Saferoads Holdings Limited reported a solid quarterly profit of $346,000, driven by strong product sales including a key order from On-site Rentals. However, the company signals caution on sustaining profitability due to market uncertainties and inventory adjustments.

Plenti Group Limited has reported a fourth straight quarter of record loan originations, driving a 24% annual growth in its loan portfolio and doubling its half-year profits. The fintech lender is accelerating towards a $3 billion loan book target by March 2026 amid strong credit performance and strategic investments.

Audio Pixels Holdings has extended the maturity of $12.3 million in convertible notes to January 2027 and capitalised $4.05 million in accrued interest, enhancing its financial flexibility.

Radiopharm Theranostics has completed a A$35 million institutional placement and launched a A$5 million Share Purchase Plan, both at $0.03 per share, to fund drug manufacturing and clinical trials through 2027.

BrainChip Holdings Ltd showcased its leadership in ultra-low-power edge AI technology, emphasizing strong partnerships and a growing product portfolio targeting high-growth sectors like defense and healthcare.

XRF Scientific has reported a robust September quarter with a 16% increase in revenue, driven by strong international sales and new product launches. The company is poised for further expansion with ongoing innovation and strategic focus on global markets.